United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 4 minute read Pharma Industry News Glenmark Pharmaceuticals expands U.S. OTC market presence with Olopatadine Eye Drops Glenmark secures FDA approval for its OTC Olopatadine Hydrochloride eye drops, expanding its U.S. presence in the $50.7M allergy relief market. byPallavi MadhirajuMarch 21, 2025